NAGE
Niagen Bioscience, Inc.Company with tickers: NAGE
CIK
1386570
CUSIP
171077407
Shares Outstanding
79,644,327
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $31,474,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | $11,498,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Gross Profit | $19,976,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Expenses | $18,400,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Research & Development | $1,481,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Operating Income | $1,576,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| Net Income | $6,318,000 | USD | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Basic) | $0.08 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |
| EPS (Diluted) | $0.07 | USD/shares | 2026-03-31 | 10-Q | 2026-05-06 |